Clinical Trial Update: Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending-dose study of XmAb®27564 in psoriasis and atopic dermatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Psoriasis

Drugs mentioned

• XmAb®27564

Snippet

Sponsor: Xencor, Inc. | Conditions: Psoriasis, Atopic Dermatitis | Phase 1 | Status: TERMINATED